Ben Adams's profile photo

Ben Adams

Chichester

Senior Editor at Fierce Biotech

Senior Editor at FiercePharma

Senior editor of Fierce Pharma Marketing

Featured in: Favicon fiercebiotech.com Favicon fiercepharma.com Favicon bmj.com Favicon wealthofgeeks.com Favicon merryjane.com Favicon 3blmedia.com Favicon architectsjournal.co.uk Favicon metroactive.com Favicon indaily.com.au Favicon pmlive.com

Articles

  • Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease

    2 weeks ago | fiercebiotech.com | Ben Adams

    CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead program, works as a long-acting, next-generation anticoagulant for thromboembolic disorders that after passing early phase 1 tests is gearing up for midstage trials.

  • GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug

    3 weeks ago | fiercebiotech.com | Ben Adams

    GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate for a hefty $1.2 billion upfront. That drug in question is efimosfermin, Boston Pharmaceuticals’ lead asset. The asset has already passed midstage tests and is in now a phase 3-ready therapy to help stop the progression of steatotic liver disease (SLD), a condition where fat builds up in the liver.

  • Arcturus stops work on early-stage vaccine programs in effort to ‘streamline resources’

    3 weeks ago | fiercebiotech.com | Ben Adams |Gabrielle Masson

    San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.

  • Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC

    4 weeks ago | fiercebiotech.com | Ben Adams

    Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical. The pact centers on MHB088C, a B7-H3-targeted antibody-drug conjugate that is in trials for solid tumors, including in subgroups of patients with small cell lung cancer and metastatic castration-resistant prostate cancer.

  • RallyBio cuts deeper, culling 40% of workforce

    1 month ago | fiercebiotech.com | Ben Adams

    RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after discontinuing its lead drug program and just over a year after a similar cost-cutting drive. These latest cuts, which affect nine roles, are set to be “substantially complete by the end of the second quarter of 2025,” the nanocap biotech said in its financial results Thursday morning.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
3K
Tweets
25K
DMs Open
No
BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
31 Oct 24

RT @FierceBiotech: Step into Fierce Biotech’s graveyard, a yearly ritual in which we remember the biotechs shuttering operations. https://t…

BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
30 Oct 24

RT @gliadkovskaya: 🏅Today's the 100th episode of #Podnosis!! To close out Menopause Awareness Month, I chatted with an OBGYN at @mavencli…

BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
27 Oct 24

RT @bmj_latest: Pharma companies have paid an estimated £156 million to NHS trusts in England between 2015 and 2022 without the public bein…